For researchers asking how long to stay on GLP-1 medications , the answer depends on individual goals and ongoing consultation with a healthcare provider
While employees with obesity do cost employers more each year, GLP1s can help provide substantial health improvements
The weight loss piece is honestly where it gets interesting though
Common experiences during dose adjustments may include: mild nausea decreased appetite feeling full sooner temporary fatigue digestive changes Gradual titration helps minimize discomfort and allows the body time to adapt
Ozempic's FDA approval Ozempic (semaglutide 0.5mg, 1mg, and 2mg) received FDA approval in December 2017 for improving blood sugar control in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
A: Retatrutide targets three metabolic pathways (GLP-1, GIP, and glucagon), while semaglutide acts on GLP-1 alone